Ziritaxestat与口服避孕药的药物相互作用:SULT1E1抑制的作用
本研究为开放标签、固定序列交叉药物相互作用研究,纳入15名健康非妊娠女性,评估ziritaxestat 600 mg每日一次对单剂量口服避孕药(0.03 mg炔雌醇/3 mg屈螺酮)暴露的影响。结果显示炔雌醇Cmax和AUC0-inf分别增加2.8倍和2.4倍,屈螺酮Cmax和AUC0-inf分别增加1.1倍和1.2倍。机制研究表明ziritaxestat通过抑制硫酸化而非CYP3A4抑制增加炔雌醇暴露。
要点
- Ziritaxestat使炔雌醇Cmax和AUC0-inf分别增加2.8倍和2.4倍。
- 屈螺酮暴露仅轻微增加(Cmax 1.1倍,AUC0-inf 1.2倍)。
- Ziritaxestat是硫酸转移酶1E1(SULT1E1)的强效抑制剂(IC50 < 0.8 μM)。
核心结论
- Ziritaxestat通过抑制硫酸化而非CYP3A4显著增加炔雌醇暴露,提示与口服避孕药合用时需关注相互作用。
研究设计与样本
- 开放标签、固定序列交叉药物相互作用研究,纳入15名健康非妊娠女性(18-65岁),使用高效避孕措施。
主要发现
- 炔雌醇Cmax和AUC0-inf分别增加2.8倍和2.4倍(第18天 vs 第1天)。
- 屈螺酮Cmax和AUC0-inf分别增加1.1倍和1.2倍。
- Ziritaxestat是SULT1E1强效抑制剂,IC50 < 0.8 μM。
- 炔雌醇葡萄糖醛酸化基本不受ziritaxestat影响。
临床怎么用
- 与ziritaxestat合用时需警惕口服避孕药中炔雌醇暴露增加带来的安全性影响。
- 评估药物相互作用时不应仅关注CYP3A4,还应考虑硫酸化等代谢途径。
局限性
- 研究样本量较小(n=15),仅纳入健康女性。
- 研究为固定序列设计,可能存在时间效应偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In vitro signals indicate that ziritaxestat is a weak cytochrome P450 (CYP) 3A4 inhibitor and inducer. Therefore, potential drug-drug interactions (DDIs) with oral contraceptives were examined at a time when ziritaxestat was under development for treatment of fibrotic diseases. This open-label, crossover (fixed sequence) DDI study enrolled healthy, nonpregnant women aged 18-65 years (n = 15) who were using highly effective contraception, such as a nonhormonal intrauterine device, bilateral tubal occlusion, or sexual abstinence. A single dose of oral contraceptive (0.03 mg ethinyl estradiol (EE) and 3 mg drospirenone (DRSP)) was administered on days 1, 8, and 18, and ziritaxestat 600 mg once daily was administered from days 8 to 23. Co-administration resulted in a 2.8-fold and 2.4-fold increase in EE maximum plasma concentration (Cmax ) and area under the plasma drug concentration-time curve from time zero to infinity (AUC0-inf ), respectively (day 18 vs. day 1). DRSP Cmax and AUC0-inf increased by 1.1-fold and 1.2-fold, respectively. DRSP is a CYP3A4 substrate, meaning increased EE exposure with ziritaxestat was not due to CYP3A4 inhibition. Ziritaxestat inhibition of EE glucuronidation and sulfation was quantified by liquid chromatography with tandem mass spectrometry in day 1 and day 18 plasma samples after EE conjugate hydrolysis. The ratio of EE AUC from time of administration up to the time of the last quantifiable concentration (AUClast ) with/without hydrolysis by arylsulfatase was substantially lower on day 18 vs. day 1, suggesting ziritaxestat is a potent inhibitor of sulfation; EE glucuronidation was largely unaffected by ziritaxestat. In vitro assessment confirmed ziritaxestat is a potent inhibitor of sulfotransferase family 1E member 1 (half-maximal inhibitory concentration < 0.8 μM). These findings highlight the importance of assessing enzymes other than CYP3A4 when investigating potential DDIs with oral contraceptives.
引用
- Helmer E, Karimian N, Van Assche K, et al. Ziritaxestat Drug-Drug Interaction with Oral Contraceptives: Role of SULT1E1 Inhibition. Clin Pharmacol Ther. 2022. PMID: 35713964. doi:10.1002/cpt.2689
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。